Cerveau Technologies and UCL collaborate to fight Alzheimer’s Disease

Our new partnership enables UCL to develop and distribute an imaging agent, furthering the understanding and treatment of neurodegenerative disease.

Cerveau develops diagnostics and technology to treat patients with neurodegenerative disorders. UCL is a leading centre for the production and application of imaging biomarkers for use in clinical research. Under this partnership, UCL will manufacture and distribute the imaging agent called [¹⁸F]MK-6240. 

UCL will use [¹⁸F]MK-6240 in clinical studies to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs are the hallmark of several neurodegenerative diseases, including Alzheimer’s Disease. The UCL Centre for Radiopharmaceutical Chemistry will be the first UK site to distribute [¹⁸F]MK-6240, which is produced according to good manufacturing practices (GMP). It will then be provided to the UCL Dementia Research Centre and the wider biomedical research community.

Rick Hiatt, President and CEO of Cerveau Technologies said: “We are enthusiastic about working with the team at UCL and making the tracer broadly accessible for investigations in the UK. We believe that the expertise and collaboration we have seen from the UCL team is a great indication of a promising collaboration between Cerveau and UCL to enable broad access for scientific research and clinical trial support.”

Further reading
UCL News story: UCL announces new collaboration with Cerveau Technologies